Gerresheimer Ag · XETR:GXI
Gerresheimer — Q1 2026 Earnings Presentation
16 slides from Gerresheimer's earnings presentation, Aug 27, 2026
Slide 1: Q1 2026 – Preliminary Results Presentation
Q1 2026 – Preliminary Results Presentation 27 August 2026
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 3: Q1 2026 Overview
Q1 2026 Overview
Slide 4: Executing on Portfolio Transformation – Post Centor & PPP divestiture, leverage below 3x
Executing on Portfolio Transformation – Post Centor & PPP divestiture, leverage at sustainable <3x level Regaining freedom to operate and continuing portfolio & operational transformation Signed divestitures on 29 July; closing Centor targeted for Nov’26 and PPP for H1 27 Refinancing aligned with cl
Slide 5: 2025 effects from restatements: Revenues ~unchanged and EBITDA -11%
2025 effects from restatements resulted in Revenues ~unchanged (-0%) and EBITDA (-11%) Q1 25 impact of corrections revenues and adjusted EBITDA (EURm) Revenues* Adj. EBITDA* 520 519 91 Δ1 81 Δ10 Bill and Hold -17 11 5 17.6% 15.7% Corrections consist of Other -12 -15 -1 -10 Q1 2025 Q1 2025 Q1 2025 Q1
Slide 6: Best Q1 FCF before M&A since 2019; Reducing CapEx to Half
Best Q1 FCF before M&A since 2019; Reducing CapEx to Half and avoiding > EUR 40m inventory build-up YoY – yet (EUR 15m) lower EBITDA As Reported Revenues, Adjusted EBITDA and Cash Flow; FX as is Revenues* (EURm) Adj. EBITDA* (EURm) FCF before M&A* (EURm) Organic growth yoy1 4.4% 524 81 519 66 -32 15
Slide 7: Preliminary Q1 2026 Financial Performance
Preliminary Q1 2026 Financial Performance
Slide 8: New Segmentation Q1 onwards - Divestitures accelerating progress
New Segmentation Q1 onwards - Divestitures accelerating progress towards High Value Primary Packaging and Drug Delivery Solutions Next: Preparing Moulded Glass Containment & Primary Injectable Moulded Glass* Delivery Systems Solutions Divestitures PPP Centor Medical Device Systems Advanced Technolog
Slide 9: Containment and Delivery Systems – Peachtree Ramp Up Coming Through
Containment and Delivery Systems – Peachtree Ramp Up Coming Through Revenues and Adj. EBITDA growth mainly driven by successful Peachtree Ramp Up in Medical Devices In EURm Revenues* Organic yoy +8.8%1 296 Revenues ▪ Increase driven by Medical Device Systems (MDS) with 281 ramp-up of Peachtree Site
Slide 10: Primary Injectable Solutions – Initiating TG Europe & Asia Restructuring
Primary Injectable Solutions – Initiating TG Europe & Asia Restructuring Syringe systems topline growth offsets lower TG Europe & Asia performance In EURm Revenues* Organic yoy +14.2%1 101 Revenues 94 ▪ Significant revenue growth in syringe systems >EUR 10m compensated by revenue decline in Tubular
Slide 11: Moulded Glass – Lower Sales Combined with Inventory Reduction
Moulded Glass – Lower Sales Combined with Inventory Reduction Led to Low Asset Utilization impacting EBITDA Topline decrease mainly US, closure Chicago Heights; lower Pharma in Europe and weaker Cosmetics In EURm Revenues* Organic yoy 160 -8.4%1 Revenues ▪ Lower revenues in parenteral type 1 (Chicag
Slide 12: Cash Rigor Paid Off: Best Q1 FCF since 2019
Cash Rigor Paid Off: Best Q1 FCF* since 2019! with (€32m) and +€109m Improvement YoY Main drivers: Less inventory build-up through extended production halts and reducing capex to half 66 Note: Q1 25 at EUR 113m = 2x 9 By Type in Q1 26: -EUR ~19m base -EUR ~37m of growth 13 By Segment in Q1 26: -EUR
Slide 13: Financing as of Prel. Q1 2026 - Solid Liquidity and Refinancing in Process
Financing as of Prel. Q1 2026 - Solid Liquidity and Refinancing in Process Solid liquidity in Q1 2026; leverage covenant suspended up and including Q3; fulsome debt refinancing at <3x leverage in process aligned with timing of Centor & PPP closing Net Financial Debt as of Preliminary Q1 2026 Maturit
Slide 14: Upcoming Events
Upcoming Events Financial Reporting and Conferences Financial Calendar Investor Conferences 2026 Preliminary 1st Quarter Kepler Cheuvreux Autumn Conference 2026 August 27, 2026 2026 Information September 9, Paris Goldman Sachs 23rd Annual European Medtech and Annual General Meeting September 1, 2026
Slide 15: Closing Remarks and Next Steps
Closing Remarks and Next Steps Roadmap defined to profitable High Value Primary Packaging and Drug Delivery Solutions Provider • Execute Centor (Nov´26) and PPP (H1 27) sale to refinance at sustainable <3x leverage • Execute Transformation (gto) Initiatives ~50/50 ´26/27 for full run rate impact in
Slide 16: innovating for a better life
innovating for a better life